ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1280

Clinical Outcomes of Juvenile Dermatomyositis Patients Treated with TNF-Inhibitors: A Retrospective Chart Review Katelyn Banschbach1, Ellen Go1 and Stacey Tarvin2, 1Indiana University School of Medicine, 2riley Hospital for Children, Indiana University

Katelyn Banschbach1, Ellen Go2 and Stacey Tarvin3, 1Indiana University School of Medicine, Indianapolis, IN, 2Pediatrics, Indiana University School of Medicine, Indianapolis, IN, 3Riley Hospital for Children, Indiana University, Indianapolis, IN

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: anti-TNF therapy, infliximab, juvenile dermatomyositis and pediatric rheumatology

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Title: Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster II: Lupus and Related Disorders, Myositis, Scleroderma and Vasculitis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: To analyze the clinical outcomes of TNF-inhibitors as a steroid-sparing agent in the treatment of juvenile dermatomyositis (JDM).

Methods: We performed a retrospective chart review on a total of 15 patients from 1997 to 2011 who were diagnosed with probable or definite JDM based on the Bohan and Peter criteria (1975). All patients were between the ages of 3-16 years at diagnosis and had exposure to TNF-inhibitor therapy. Patient demographic information, clinical history, medication history including dose, time between diagnosis and TNF-inhibitor use, and significant adverse events were reviewed. Outcome was defined based on medication changes, clinical history, and presence of adverse events.

Results: Infliximab was the most frequently administered TNF-inhibitor. Ten patients were treated with infliximab, four with etanercept, and one with adalimumab. Infliximab dose ranged from 3 to 15mg/kg/dose every 4 weeks. Twelve of 15 patients had at least a 50% reduction in oral steroid dose after TNF therapy and 20% of all patients were able to stop all medications. In the infliximab cohort, 60% were able to discontinue steroids and 30% were able to reduce the steroid dose by half. Among patients that improved, average time from diagnosis to initiation of TNF therapy was 12 (±11.6) months. All patients received methotrexate and oral steroids prior to initiation of an anti-TNF agent. In addition, 10 patients were previously treated with IV methylprednisolone (IVMP), 10 with IV immunoglobulin, and 5 with hydroxychloroquine. Three patients were on IVMP at the start of TNF therapy and two discontinued the IVMP infusions while taking biologics. Three patients had infections that resulted in discontinuation of anti-TNF medications. Two patients, both taking infliximab, required hospitalization. There were no reported deaths or incidence of malignancy. In all patients, TNF therapy was held for infection and was not restarted due to baseline stability of disease.

Conclusion: JDM is the most common inflammatory myopathy in children. It is a multisystem disorder associated with significant morbidity and risk of long-term disability if untreated. In this cohort, TNF-inhibitors were typically used as a 3rd or 4th line therapy. The majority of infliximab-treated patients had a substantial decrease in overall steroid exposure and a significant percentage were able to stop steroids. Infection was the most common adverse event reported but this did not lead to any life-threatening morbidity and reversed after discontinuing the biologic. The use of TNF-inhibitors in JDM patients is still controversial. However, this data supports further investigation into the use of TNF-inhibitors, particularly infliximab, as a therapeutic option in children with refractory JDM.


Disclosure: K. Banschbach, None; E. Go, None; S. Tarvin, None.

To cite this abstract in AMA style:

Banschbach K, Go E, Tarvin S. Clinical Outcomes of Juvenile Dermatomyositis Patients Treated with TNF-Inhibitors: A Retrospective Chart Review Katelyn Banschbach1, Ellen Go1 and Stacey Tarvin2, 1Indiana University School of Medicine, 2riley Hospital for Children, Indiana University [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/clinical-outcomes-of-juvenile-dermatomyositis-patients-treated-with-tnf-inhibitors-a-retrospective-chart-review-katelyn-banschbach1-ellen-go1-and-stacey-tarvin2-1indiana-university-s/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-outcomes-of-juvenile-dermatomyositis-patients-treated-with-tnf-inhibitors-a-retrospective-chart-review-katelyn-banschbach1-ellen-go1-and-stacey-tarvin2-1indiana-university-s/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology